N(ε)-(carboxymethyl)lysine in blood from maintenance hemodialysis patients may contribute to dialysis-related amyloidosis

Kidney International

Volumn 54, Issue 4, 1998, Pages 1357-1366

  Motomiya, Yoshihiro ^a   Oyama, Nobuo ^b   Iwamoto, Hisahiko ^b   Uchimura, Tomonori ^b   Maruyama, Ikuro ^b  

^a Suiyukai Clinic   (Japan)

^b NONE

Author keywords

Advanced glycation end product; AGE; B2 microglobulin; Biomarker; CML Hb; Hemodialysis; Oxidative damage; Uremia

Indexed keywords

BETA 2 MICROGLOBULIN; N (CARBOXYMETHYL)LYSINE; UNCLASSIFIED DRUG; ADVANCED GLYCATION END PRODUCT; BIOLOGICAL MARKER; DRUG DERIVATIVE; HEMOGLOBIN; LYSINE; METHYLGUANIDINE; N(6) CARBOXYMETHYLLYSINE; N(6)-CARBOXYMETHYLLYSINE;

ADULT; AGED; AMYLOIDOSIS; ANTIBODY PRODUCTION; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE MARKER; FEMALE; HEMODIALYSIS PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN GLYCOSYLATION; ANIMAL; BLOOD; CARPAL TUNNEL SYNDROME; ENZYME LINKED IMMUNOSORBENT ASSAY; MASS SPECTROMETRY; METABOLISM; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; RABBIT; RENAL REPLACEMENT THERAPY; SPINE DISEASE;

ADULT; AGED; AGED, 80 AND OVER; AMYLOIDOSIS; ANIMALS; BETA 2-MICROGLOBULIN; BIOLOGICAL MARKERS; CARPAL TUNNEL SYNDROME; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GLYCOSYLATION END PRODUCTS, ADVANCED; HEMOGLOBINS; HUMANS; LYSINE; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MASS SPECTROMETRY; METHYLGUANIDINE; MIDDLE AGED; RABBITS; RENAL DIALYSIS; SPINAL DISEASES;

EID: 0031595043     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.1998.00091.x     Document Type: Article

References (40)

1. THORPE SR, BAYNES JW: Role of the Maillard reaction in diabetes mellitus and diseases of aging. Drugs Aging 2:64-77, 1996
2. BROWNLEE M, CERAMI A, VLASSARA H: Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications, N Engl J Med 318:1315-1321, 1988
3. VLASSARA H: Protein glycation in the kidney. Role in diabetes and aging. Kidney Int 49:1795-1804, 1996
4. MIYATAT, MAEDA K, KUROKAWA K, VAN YPERSELE DE STRIHOU C: Hypothesis oxidation conspires with glycation to generate noxious advanced glycation end products in renal failure. Nephrol Dial Transplant 12:255-258, 1997
5. GLOMB MA, MONNIER VM: Mechanism of protein modification by glyoxal and glycoaldehyde, roative intermediates of the Maillard reaction. J Biol Chem 270:10017-10026, 1995
6. WOLFF SP, DEAN RT: Glucose autoxidation and protein modification. The potential role of 'autoxidative glycosylation' in diabetes. Bochem J 245:243-250, 1987
7. WELLS-KNECHT KJ, ZYZAK DV, LITCHFIELD JE, THORPE SR, BAYNES JW: Mechanism of autoxidative glycosylation: Identification of glyoxal and arabinose as intermediates in the autoxidative modification of proteins by glucose. Biochemistry 34:3702-3709, 1995
8. ε (carboxymethyl)lysine, a constituent of human urine. Clin Chim Acta 59:313-320, 1975
9. ε-(carboxymethyl)lysine as a degradation product of fructose lysine in glycated protein. J Biol Chem 261:4889-4894, 1986
10. ε-(carboxymethyl) lysine is a dominant advanced glycation end product (AGE) antigen in tissue proteins. Biochemistry 34:10872-10878, 1995
11. ε-(carboxymethyl)lysine protein adduct is a major immunological epitope in proteins modified with advanced glycation end products of the Maillard reaction. Biochemistry 35:8075-8083, 1996
12. ε-(carboxymethyl)lysine in dialysis-related amyloidosis. Kidney Int 50:1303-1309, 1996
13. MAKITA Z, RADOFF S, RAYFIELD EJ, YANG Z, SKOLNIK E, DELANEY V, FRIEDMAN EA, CERAMI A, VLASSARA H: Advanced glycosylation end products in patients with diabetic nephropathy. N Engl J Med 325:836-842, 1991
14. MAKITA Z, VLASSARA H CERAMI A, BUCALA R: Immunochemical detection of advanced glycosylation end products in vivo. J Biol Chem 267:5133-5138, 1992
15. TAKAHASHI M, KUSHIDA K, KAWANA K, ISHIDA C, DENDA M, INOUE T, HORIUCHI K: Quantification of the cross- link pentosidine in serum from normal and uremic subjects. Clin Chem 39:2162-2165, 1993
16. ODETTI P, FOGARTY J, SELL DR, MONNIER VM: Chromatographic quantitation of plasma and erythrocyte pentosidine in diabetic and uremic subjects. Diabetes 41:153-159, 1992
17. MIYATA T, UEDA Y, SHINZATO T, IIDA Y, TANAKA S, KUROKAWA K, VAN YPERSELE DE STRIHOU C, MAEDA K: Accumulation of albumin-linked and free-form pentosidine in the circulation of uremic patients with end-stage renal failure: Renal implications in the pathophysiology of pentosidine. J Am Soc Nephol 7:1198-1206, 1996
18. ε-(calboxymethyl)hydroxylysine in human skin collagen. Biochemistry 30:1205-1210, 1991
19. GLASSY MC, CLEVELAND PH: Use of mouse and human monoclonal antibodies in enzyme immunofiltration. Methods Enzymol 121:525-541, 1986
20. NAKAJIMA M, NAKAMURA K, SHIRAKANE Y, HIRASAWA Y: Enzymic determination of methylguanidine in serum and plasma of hemodialysis patients as a marker for hydroxy radicals, in Guanidines (2nd ed), New York, Plenum Publishing Corp., 1989, pp 3-16
21. VAN YPERSELE DE STRIHOU C, JADOUL M, MALGHEM J, MALDAGUE B, JAMART J, THE WORKING PARTY ON DIALYSIS-AMYLOIDOSIS: Effect of dialysis membrane and patient's age on signs of dialysis-related amyloidosis. Kidney Int 39:1012-1019, 1991
22. GEJYO F, SUZUKI S, KIMURA H, IMURA T, EI I, HASEGAWA H, ARAKAWA M: Increased risk of dialysis-related amyloidosis in patients with the apolipoprotein E4 allele, amyloid. Int J Exp Clin Invest 4:13-17, 1997
23. GEJYO F, YAMADA T, ODANI S, NAKAGAWAY, ARAKAWA M, KUNITOMO T, KATAOKA H, SUZUKI M, HIRASAWA Y, SHIRAHAMA T, COHEN AS, SCHMID K: A new form of amyloid protein associated with chronic hemodialysis was identified as β2-microglobulin. Biochem Biophys Res Commun 129:701-706, 1985
24. MIYATA T, TANEDA S, KAWAI R, UEDA Y, HORIUCHI S, HARA M, MAEDA K, MONNIER VM: Identification of pentosidine as a native structure for advanced glycation end products in β2-microglobulin-containing amyloid fibrils in patients with dialysis-related amyloidosis Proc Natl Acad Sci USA 93:2353-2358, 1996
25. PAPANASTASIOU P, GRASS L, RODELA H, PATRIKAREA A, OREOPOULES D, DIAMANDIS EP: Immunological quantification of advanced glycosylation end-products in the serum of patients on hemodialysis or CAPD. Kidney Int 46:216-222, 1994
26. NIWA T, KATSUZAKI T, MOMOI T, MIYAZAKI T, OGAWA H, SAITO A, MIYAZAKI S, MAEDA K, TATEMICHI N, TAKEI Y: Modification of β2-microglobulin with advanced glycation end products as observed in dialysis-related amyloidosis by 3-DG accumulating in uremic serum. Kidney Int 49:861-867, 1996
27. NIWA T, TAKEDA N, MIYAZAKI T, YOSHIZUMI H, TATEMATSU A, MAEDA K, OHARA M, TOMIYAMA S, NIIMURA K: Elevated serum levels of 3-deoxyglucosone, a potent protein-cross-linking intermediate of the Maillard reaction, in uremic patients. Nephron 64:438-443, 1995
28. HAMADA Y, ARAKI N, HORIUCHI S, HOTTA N: Role of polyol pathway in nonenzymatic glycation. Nephrol Dial Transplant 2(Suppl 5):95-98, 1996
29. ε-(calboxymethyl)lysine (CML), is a product of both lipid peroxidation and glycoxidation reactions. J Biol Chem 271:9982-9986, 1996
30. ε-(carboxymethyl)lysine by reaction between lysine and products of autoxidation of ascorbate. Biochemistry 29:10964-10970, 1990
31. MIYATA T, WADA Y, CAI Z, IIDA Y, HORIE K, YASUDA Y, MAEDA K, KUROKAWA K, VAN YPERSELE DE STRIHOU C: Implication of an increased oxidative stress in the formation of advanced glycation end products in patients with end-staae renal failure. Kidney Int 51:1170-1181, 1997
32. LOUGHREY CM, YOUNG IS, KIGHTBODY JH, MCMASTER D, MCNAMEE PT, TRIMBLE ER: Oxidative stress in haemodialysis. Quart J Med 87:674-683, 1994
33. WITKO SV, FRIEDLANDER M, CAPEILLERE BC, NGUYEN-KT, NGUYEN-AT, ZINGRAFF J, JUNGERS P, DESCAMPS-LATSHA B: Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int 49:1304-1313, 1996
34. ε-(carboxymethyl)lysine is increased in uremia. Kidney Int 52:1064-1067, 1997
35. ε-(carboxymethyl)lysine in human tissues in diabetes and aging. J Clin Invest 99:457-468, 1997
36. NAGASE S, AOYAGI K, NARITA K, TOJO S: Active oxygen in methylguanidine synthesis. Nephron 44:299-303, 1986
37. OZAWA H, WATANABE T, NAKAMURA K, FUKUNAGA Y, IENAGA K, HAGIWARA K: Changes in serum levels of creatol and methylguanidine in renal injury induced by lipid peroxide produced by vitamin E deficiency and GSH depletion in rats. Nephron 75:224-229, 1997
38. TURNEY JH, DAVISON AM, FORBES MA, COOPER EH: Hyaluronic acid in end-stage renal failure treated by haemodialysis: Clinical correlates and implications. Nephrol Dial Transplant 6:566-570, 1991
39. OZAWA H, CHICHIBU K, TANAKA Y, KONDO T, KITAJIMA K, OTA K: Relationship between plasma levels of hyaluronic acid and amyloid-associated osteoarthropathy in chronic hemodialysis patients. Nephron 61:187-191, 1992
40. ε-microglobulin amyloidosis in hemodialysis: A prospective post-mortem study. Kidney Int 51:1928-1932, 1997